To continue using this website, please tell us a
little about yourself:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies on the website and how to delete cookies, see our Privacy and Cookie Policy.

I accept the FE Trustnet cookie policy

For more information Click here



It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table

Polar Capital Biotechnology

Change Share Class?

Polar Capital Biotechnology I USD
Select Performance Currency
Pound Sterling
  • What is the Fund’s objective?

    The Fund aims to preserve capital and achieve long-term capital appreciation by investing throughout the biotechnology ecosystem, across geographies and market capitalisations.

    How does FE rate this fund?

    • No FE Alpha managers
    • Not included in the AFI

    Who manages this fund?

    David Pinniger Since 01-Nov-2013

    David joined Polar Capital in August 2013 as a Fund Manager within the healthcare team. He has over 14 years’...

    Primary manager

  • How has this fund performed?

    Cumulative Performance chart

    Cumulative Performance as at 28/04/2017
        3m 6m 1yr 3yrs 5yrs
    Polar Capital Biotechnology I USD +5.4 +16.7 +39.2 +118.7 n/a
    IA Specialist +1.7 +1.8 +21.5 +26.4 +31.9

    Discrete Performance chart

  • Forensic News Alerts

  • Ratios and Analysis

    Ratio Info

        1y 3y
    ? Volatility 23.27 24.00
    ? Alpha 17.87 18.84
    ? Beta 1.33 0.94
    ? Sharpe 1.17 0.46
    ? Info Ratio 0.92 0.75
    ? R2 0.23 0.21

    Risk Score

    FE Risk scores allow you to see how risky a fund is in comparison with the FTSE 100.

    This fund: 198
    FTSE 100: 100
    Cash: 0

    Investment Details

    Initial 5.00%
    Annual 1.00%
    ? OCF 1.17%
    Minimum Investment?
    Initial £ 1,000,000
    Additional n/a
  • Prices

      Unit type Currency Bid Offer Date Yield Citicode SEDOL ISIN
    Polar Capital Biotechnology I USD INC USD 19.63 27 Apr 2017 n/a JTYG B42Z453 IE00B42Z4531

    Change the share class at the top of the page to see details of other share classes for this fund.

  • What does this fund invest in?

    Asset Class Breakdown (28 Feb 2017)

    Rank Asset %    
    1 US Equities 71.60
    2 Danish Equities 7.00
    3 UK Equities 4.20
    4 Chinese Equities 4.10
    5 Swedish Equities 3.60
    6 Irish Equities 3.40
    7 German Equities 1.40
    8 French Equities 1.30
    9 Cash 1.30
    10 Others 2.10

    Top Holdings (28 Feb 2017)

    Rank Largest Holdings %  
    1 CELGENE CORP 7.15
    2 INCYTE CORP 6.00
    4 GENMAB AS 4.82
    5 BIOGEN INC 4.60
    7 BEIGENE LTD 4.05
    8 AMGEN INC 4.04
    9 TESARO INC 3.92
  • Additional Information

    Additional Information

    Legal Structure: OEIC
    Own ISA wrapper: NO
    Trustee / Depositary: Northern Trust Fiduciary Services (Ireland) Limited
    Registrar: Northern Trust International Fund Administration S
    Multi-Manager: Manager Of Managers
    Dividend policy: Jan 01 (Final)
    Fund size: £121.3m / $157.0m (13-Apr-17)
    Unit Launch: 31-Oct-2013
    Fund Launch: 31-Oct-2013
    Savings plan: NO
    Pricing times: 16:00
    Dealing times: Daily 17:00 (Dublin time)
    Dealing frequency: Daily
  • News and Research about this fund

    Relevant articles

    Relevant Guides

  • Contact Details

    16 Palace Street, London, London, SW1E 5JD

    020 7227 2799 (Fax Number)
    020 7227 2700 (Main Number)

Initial Charges: max.;

Price total return performance figures are calculated on a bid price to bid price basis (mid to mid where applicable) with gross income (dividends) reinvested. Performance figures are shown in selected currency.

Your custom layout changed and saved automatically
Drag and drop the icon to customise your factsheet layout
Data provided by FE. Care has been taken to ensure that the information is correct, but FE neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close